Misoprostol Explained

Watchedfields:changed
Verifiedrevid:456483721
Width:200
Tradename:Cytotec, Misodel, others
Dailymedid:Misoprostol
Pregnancy Au:X
Pregnancy Au Comment:[1] [2]
Pregnancy Category:Used for terminating pregnancy
Routes Of Administration:By mouth, rectal vaginal, under the tongue
Atc Prefix:A02
Atc Suffix:BB01
Legal Au:S4
Legal Au Comment:[3]
Legal Br:C1
Legal Br Comment:Hospital use only[4]
Legal Ca:Rx-only
Legal Uk:POM
Legal Uk Comment:[5]
Legal Us:Rx-only
Legal Us Comment:[6]
Legal Eu:Rx-only
Legal Eu Comment:[7] [8]
Bioavailability:extensively absorbed
Protein Bound:80–90% (active metabolite, misoprostol acid)
Metabolism:Liver (extensive to misoprostic acid)
Elimination Half-Life:20–40 minutes
Excretion:Urine (80%)
Cas Number:59122-46-2
Pubchem:5282381
Iuphar Ligand:1936
Drugbank:DB00929
Chemspiderid:4445541
Unii:0E43V0BB57
Kegg:D00419
Chembl:606
Iupac Name:Methyl 7-((1R,2R,3R)-3-hydroxy-2-((S,E)-4-hydroxy-4-methyloct-1-enyl)-5-oxocyclopentyl)heptanoate
C:22
H:38
O:5
Smiles:CCCC[C@](C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
Stdinchi:1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1
Stdinchikey:OJLOPKGSLYJEMD-URPKTTJQSA-N

Misoprostol is a synthetic prostaglandin medication used to prevent and treat stomach and duodenal ulcers, induce labor, cause an abortion, and treat postpartum bleeding due to poor contraction of the uterus.[9] [10] It is taken by mouth when used to prevent gastric ulcers in people taking nonsteroidal anti-inflammatory drugs (NSAID).[10] For abortions it is used by itself or in conjunction with mifepristone or methotrexate.[11] By itself, effectiveness for abortion is between 66% and 90%.[12] [13] For labor induction or abortion, it is taken by mouth, dissolved in the mouth, or placed in the vagina.[14] [15] [16] For postpartum bleeding it may also be used rectally.[17]

Common side effects include diarrhea and abdominal pain.[10] It is in pregnancy category X, meaning that it is known to result in negative outcomes for the fetus if taken during pregnancy.[10] In rare cases, uterine rupture may occur.[10] It is a prostaglandin analogue—specifically, a synthetic prostaglandin E1 (PGE1).[10]

Misoprostol was developed in 1973.[18] It is on the World Health Organization's List of Essential Medicines.[19] It is available as a generic medication.[10]

Medical uses

Ulcer prevention

Misoprostol is used for the prevention of NSAID-induced gastric ulcers. It acts upon gastric parietal cells, inhibiting the secretion of gastric acid by G-protein coupled receptor-mediated inhibition of adenylate cyclase, which leads to decreased intracellular cyclic AMP levels and decreased proton pump activity at the apical surface of the parietal cell. Misoprostol is sometimes coprescribed with NSAIDs to prevent their common adverse effect of gastric ulceration (e.g., with diclofenac in Arthrotec).

However, even in the treatment of NSAID-induced ulcers, omeprazole proved to be at least as effective as misoprostol,[20] but was significantly better tolerated, so misoprostol should not be considered a first-line treatment. Misoprostol-induced diarrhea and the need for multiple daily doses (typically four) are the main issues impairing compliance with therapy.

Labor induction

Misoprostol is commonly used for labor induction. It causes uterine contractions and the ripening (effacement or thinning) of the cervix.[21] It can be less expensive than the other commonly used ripening agent, dinoprostone.

Oxytocin has long been used as the standard agent for labor induction, but does not work well when the cervix is not yet ripe. Misoprostol also may be used in conjunction with oxytocin.[22]

Between 2002 and 2012, a misoprostol vaginal insert was studied, and was approved in the EU.[23] [24] [25] It was not approved for use in the United States, and the US FDA still considers cervical ripening and labor induction to be outside of the approved uses for misoprostol.[26] [27]

Myomectomy

When administered prior to myomectomy in women with uterine fibroids, misoprostol reduces operative blood loss and requirement of blood transfusion.[28]

Abortion

Misoprostol is used either alone or in conjunction with another medication (mifepristone or methotrexate) for medical abortions as an alternative to surgical abortion.[29] Medical abortion has the advantage of being less invasive, and more autonomous, self-directed, and discreet. It is preferred by some women because it feels more natural, as the drugs induce a miscarriage.[30] It is also more easily accessible in places where abortion is illegal.[31] The World Health Organization (WHO) provides clear guidelines on the use, benefits and risks of misoprostol for abortions.[32]

Misoprostol is most effective when it is used in combination with methotrexate or mifepristone (RU-486).[33] Mifepristone blocks signaling by progesterone, causing the uterine lining to degrade, the blood vessels of the cervix and uterus to dilate and causing uterine contraction, similar to a menstrual period, which causes the embryo to detach from the uterine walls.[34] Misoprostol then dilates the cervix and induces muscle contractions which clear the uterus. Misoprostol alone is less effective (typically 88% up to eight-weeks gestation). It is not inherently unsafe if medically supervised, but 1% of women will have heavy bleeding requiring medical attention, some women may have ectopic pregnancy, and the 12% of pregnancies that continue after misoprostol failure are more likely to have birth defects and are usually followed up with a more effective method of abortion.[35]

Most large studies recommend a protocol for the use of misoprostol in combination with mifepristone.[36] [37] Together they are effective in around 95% for early pregnancies.[38] Misoprostol alone may be more effective in earlier gestation.[39]

Misoprostol can also be used to dilate the cervix in preparation for a surgical abortion, particularly in the second trimester (either alone or in combination with osmotic dilators). Vaginal misoprostol can also be used to facilitate intrauterine device insertion after previous insertion failure.[40]

Misoprostol by mouth is the least effective treatment for producing complete abortion in a period of 24 hours due to the liver's first-pass effect which reduces the bioavailability of the misoprostol. Vaginal and sublingual routes result in greater efficacy and extended duration of action because these routes of administration allow the drug to be directly absorbed into circulation by bypassing the liver first-pass effect.[41]

Hematocrit or Hb tests and Rh testing are recommended before use for abortion confirmation of pregnancy.[42] Following use, it is recommended that people attend a follow-up visit 2 weeks after treatment. If used for treatment of complete abortion, a pregnancy test, physical examination of the uterus, and ultrasound should be performed to ensure success of treatment. Surgical management is possible in the case of failed treatment.

Early pregnancy loss

Misoprostol may be used to complete a miscarriage or missed abortion when the body does not expel the embryo or fetus on its own. Compared to no medication or placebo, it could decrease the time to complete expulsion.[43] Use of a single dose of misoprostol vaginally or buccally is preferred, with additional doses as needed. It also can be used in combination with mifepristone, with a similar regimen to medical abortion.[41]

Misoprostol is regularly used in some Canadian hospitals for labour induction for fetal deaths early in pregnancy, and for termination of pregnancy for fetal anomalies. A low dose is used initially, then doubled for the remaining doses until delivery. In the case of a previous Caesarian section, however, lower doses are used.

Postpartum bleeding

Misoprostol is also used to prevent and treat post-partum bleeding. Orally administered misoprostol was marginally less effective than oxytocin.[44] The use of rectally administered misoprostol is optimal in cases of bleeding; it was shown to be associated with lower rates of side effects compared to other routes. Rectally administered misoprostol was reported in a variety of case reports and randomised controlled trials.[45] [46] However, it is inexpensive and thermostable (thus does not require refrigeration like oxytocin), making it a cost-effective and valuable drug to use in the developing world.[47] A randomised control trial of misoprostol use found a 38% reduction in maternal deaths due to post partum haemorrhage in resource-poor communities.[48] Misoprostol is recommended due to its cost, effectiveness, stability, and low rate of side effects.[49] Oxytocin must also be given by injection, while misprostol can be given orally or rectally for this use, making it much more useful in areas where nurses and physicians are less available.[50]

Insertion of intrauterine contraceptive device

In women with prior caesarean section or prior failure of insertion of an intrauterine contraceptive device, pre-procedure administration of misoprostol reduces the rate of failure of insertion of intrauterine contraceptive device. However, due to a higher rate of adverse effects, routine use of misoprostol for this purpose in other women is not supported by the data.[51]

Other

For cervical ripening in advance of endometrial biopsy to reduce the need for use of a tenaculum or cervical dilator.

There is limited evidence supporting the use of misoprostol for the treatment of trigeminal neuralgia in patients with multiple sclerosis.[52] [53]

Adverse effects

The most commonly reported adverse effect of taking misoprostol by mouth for the prevention of stomach ulcers is diarrhea. In clinical trials, an average 13% of people reported diarrhea, which was dose-related and usually developed early in the course of therapy (after 13 days) and was usually self-limiting (often resolving within 8 days), but sometimes (in 2% of people) required discontinuation of misoprostol.[54]

The next most commonly reported adverse effects of taking misoprostol by mouth for the prevention of gastric ulcers are: abdominal pain, nausea, flatulence, headache, dyspepsia, vomiting, and constipation, but none of these adverse effects occurred more often than when taking placebos.[54]

There are increased side effects with sublingual or oral misoprostol, compared to a low dose (400 μg) vaginal misoprostol. However, low dose vaginal misoprostol was linked with low complete abortion rate.[55] The study concluded that sublingually administered misoprostol dosed at 600 μg or 400 μg had greater instances of fever and diarrhea due to its quicker onset of action, higher peak concentration and bioavailability in comparison to vaginal or oral misoprostol.

For the indication of medical abortion, bleeding and cramping is commonly experienced after administration of misoprostol. Bleeding and cramping is likely to be greater than that experienced with menses, however, emergency care is advised if bleeding is excessive.

Misoprostol should not be taken by pregnant women with wanted pregnancies to reduce the risk of NSAID-induced gastric ulcers because it increases uterine tone and contractions in pregnancy, which may cause partial or complete abortions, and because its use in pregnancy has been associated with birth defects.[54] [56]

All cervical ripening and induction agents can cause uterine hyperstimulation, which can negatively affect the blood supply to the fetus and increases the risk of complications such as uterine rupture.[57] Concern has been raised that uterine hyperstimulation that occurs during a misoprostol-induced labor is more difficult to treat than hyperstimulation during labors induced by other drugs.[58] Because the complications are rare, it is difficult to determine if misoprostol causes a higher risk than do other cervical ripening agents. One estimate is that it would require around 61,000 people enrolled in randomized controlled trials to detect a difference in serious fetal complications and about 155,000 people to detect a difference in serious maternal complications.[59]

Contraindications

It is recommended that medical treatment for missed abortion with misoprostol should only be considered in people without the following contraindications: suspected ectopic pregnancy, use of non-steroidal drugs, signs of pelvic infections or sepsis, unstable hemodynamics, known allergy to misoprostol, previous caesarean section, mitral stenosis, hypertension, glaucoma, bronchial asthma, and remote areas without a hospital nearby.

Pharmacology

Mechanism of action

Misoprostol, a prostaglandin analogue, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix. Misoprostol binds to and stimulates prostaglandin EP2 receptors, prostaglandin EP3 receptor and prostaglandin EP4 receptor but not prostaglandin EP1 receptor and therefore is expected to have a more restricted range of physiological and potentially toxic actions than prostaglandin E2 or other analogs which activate all four prostaglandin receptors.[60]

Society and culture

In August 2000, a letter from G.D. Searle, LLC, the inventor of the drug,[61] [62] generated controversy by warning against its use by pregnant women because of its ability to induce abortion, citing reports of maternal and fetal deaths when it was used to induce labor.[63] The American College of Obstetricians and Gynecologists holds that substantial evidence supports the use of misoprostol for induction of labor, a position it reaffirmed in response to the Searle letter.[64] It is on the World Health Organization's List of Essential Medicines.

A vaginal form of the medication is sold in the EU under the names Misodel[65] and Mysodelle[66] for use in labor induction.

Black market

Misoprostol is used for self-induced abortions in Brazil, where black market prices exceed US$100 per dose. Illegal medically unsupervised misoprostol abortions in Brazil are associated with a lower complication rate than other forms of illegal self-induced abortion, but are still associated with a higher complication rate than legal, medically supervised surgical and medical abortions. Failed misoprostol abortions are associated with birth defects in some cases.[67] [68] [69] [70] [71] Low-income and immigrant populations in New York City have also been observed to use self-administered misoprostol to induce abortions, as this method is much cheaper than a surgical abortion (about $2 per dose).[72] The drug is readily available in Mexico.[73] Use of misoprostol has also increased in Texas in response to increased regulation of abortion providers.[74] Following the United States Supreme Court decision of Dobbs v. Jackson Women's Health Organization, many states restricted access to legal abortion services, including medication abortion using misoprostol. As a result of these restrictions, it was reported that there was an increase in self-managed abortions by women in the United States. Many women purchased the pills from overseas online pharmacies or obtained misoprostol from Mexico.[75]

Notes and References

  1. Web site: TGA eBS - Product and Consumer Medicine Information Licence . 14 April 2023 . 14 April 2023 . https://web.archive.org/web/20230414033450/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2023-PI-01073-1 . live .
  2. Web site: TGA eBS - Product and Consumer Medicine Information Licence . 14 April 2023 . 14 April 2023 . https://web.archive.org/web/20230414031955/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05416-3 . live .
  3. Web site: Angusta (Norgine Pty Ltd) . Therapeutic Goods Administration (TGA) . 13 January 2023 . 9 April 2023 . 18 March 2023 . https://web.archive.org/web/20230318025815/https://www.tga.gov.au/resources/prescription-medicines-registrations/angusta-norgine-pty-ltd . live .
  4. Web site: Anvisa . Brazilian Health Regulatory Agency . 2023-03-31 . RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 2023-08-03 . 2023-08-15 . . pt-BR . 2023-04-04.
  5. Web site: Angusta 25 microgram tablets - Summary of Product Characteristics (SmPC) . (emc) . 8 April 2022 . 9 April 2023 . 10 April 2023 . https://web.archive.org/web/20230410051926/https://www.medicines.org.uk/emc/product/12147/smpc . live .
  6. Web site: Cytotec- misoprostol tablet . DailyMed . 9 July 2021 . 13 April 2023 . 18 April 2023 . https://web.archive.org/web/20230418121539/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ab12da7-5731-4e06-bf1c-bc3f2e711f12 . live .
  7. Web site: List of nationally authorised medicinal products. Misoprostol (gastrointestinal indication). Procedure no.: PSUSA/00010353/202005 . European Medicines Agency . 14 January 2021 . 8 August 2021 . 29 June 2022 . https://web.archive.org/web/20220629032409/https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-labour-induction-list-nationally-authorised-medicinal-products/00010353/202005_en.pdf . live .
  8. Web site: List of nationally authorised medicinal products. Misoprostol (gastrointestinal indication). Procedure no.: PSUSA/00010291/202006 . European Medicines Agency . 14 January 2021 . 8 August 2021 . 29 June 2022 . https://web.archive.org/web/20220629032409/https://www.ema.europa.eu/en/documents/psusa/misoprostol-gastrointestinal-indication-list-nationally-authorised-medicinal-products-psusa/00010291/202006_en.pdf . live .
  9. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, McGowan J . 6 . 1052260 . Prevention of NSAID-induced gastroduodenal ulcers . The Cochrane Database of Systematic Reviews . 4 . CD002296 . 2002 . 2011 . 12519573 . 10.1002/14651858.CD002296 . 8439413 .
  10. Web site: Misoprostol. The American Society of Health-System Pharmacists. 20 February 2015. live. https://web.archive.org/web/20150221072240/http://www.drugs.com/monograph/misoprostol.html. 21 February 2015.
  11. Zhang J, Zhou K, Shan D, Luo X . Medical methods for first trimester abortion . The Cochrane Database of Systematic Reviews . 2022 . CD002855 . May 2022 . 5 . 35608608 . 9128719 . 10.1002/14651858.CD002855.pub5 .
  12. Bryant AG, Regan E, Stuart G . 28486936 . An overview of medical abortion for clinical practice . Obstetrical & Gynecological Survey . 69 . 1 . 39–45 . January 2014 . 25102250 . 10.1097/OGX.0000000000000017 .
  13. Raymond EG, Harrison MS, Weaver MA . Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review . Obstetrics and Gynecology . 133 . 1 . 137–147 . January 2019 . 30531568 . 6309472 . 10.1097/AOG.0000000000003017 .
  14. Marret H, Simon E, Beucher G, Dreyfus M, Gaudineau A, Vayssière C, Lesavre M, Pluchon M, Winer N, Fernandez H, Aubert J, Bejan-Angoulvant T, Jonville-Bera AP, Clouqueur E, Houfflin-Debarge V, Garrigue A, Pierre F . 6 . Overview and expert assessment of off-label use of misoprostol in obstetrics and gynaecology: review and report by the Collège national des gynécologues obstétriciens français . European Journal of Obstetrics, Gynecology, and Reproductive Biology . 187 . 80–4 . April 2015 . 25701235 . 10.1016/j.ejogrb.2015.01.018 .
  15. Prager S . Early Pregnancy Loss . ACOG Practice Bulletin . 200 . ACOG . 2 June 2021 . 2 June 2021 . https://web.archive.org/web/20210602215845/https://static1.squarespace.com/static/5d3a2e1399c0960001b14452/t/5dc2031df1ffb26c011ff481/1572995870418/ACOG+EPL+Bulletin_update.pdf . live .
  16. Web site: Early Pregnancy Loss . ACOG . 20 January 2015 . 25 June 2023 . 19 January 2023 . https://web.archive.org/web/20230119024855/https://www.acog.org/en/clinical/clinical-guidance/practice-bulletin/articles/2018/11/early-pregnancy-loss . live .
  17. Blum J, Alfirevic Z, Walraven G, Weeks A, Winikoff B . Treatment of postpartum hemorrhage with misoprostol . International Journal of Gynaecology and Obstetrics . 99 . Suppl 2 . S202-5 . December 2007 . 17961565 . 10.1016/j.ijgo.2007.09.013 . 10997666 .
  18. Book: Paul M. Management of Unintended and Abnormal Pregnancy: Comprehensive Abortion Care. 2011. John Wiley & Sons. 9781444358476. https://books.google.com/books?id=iK7xrRr2p9sC&pg=RA1-PT161. Misoprostol. 18 August 2020. 29 June 2022. https://web.archive.org/web/20220629032410/https://books.google.com/books?id=iK7xrRr2p9sC&pg=RA1-PT161. live.
  19. Book: ((World Health Organization)) . World Health Organization model list of essential medicines: 22nd list (2021) . 2021 . 10665/345533 . World Health Organization . World Health Organization . Geneva . WHO/MHP/HPS/EML/2021.02 . free .
  20. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND . 6 . Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group . The New England Journal of Medicine . 338 . 11 . 727–34 . March 1998 . 9494149 . 10.1056/NEJM199803123381105 . 2445/178575 . free .
  21. Goldberg AB, Greenberg MB, Darney PD . Misoprostol and pregnancy . The New England Journal of Medicine . 344 . 1 . 38–47 . January 2001 . 11136959 . 10.1056/NEJM200101043440107 .
  22. Summers L . Methods of cervical ripening and labor induction . Journal of Nurse-Midwifery . 42 . 2 . 71–85 . 1997 . 9107114 . 10.1016/S0091-2182(96)00138-3 .
  23. Misodel, Ferring's Removable Misoprostol Vaginal Delivery System, Approved for Labour Induction in European Decentralised Procedure . Ferring Pharmaceuticals . Business Wire . 17 October 2013 . 25 June 2023.
  24. Wing DA, Brown R, Plante LA, Miller H, Rugarn O, Powers BL . Misoprostol vaginal insert and time to vaginal delivery: a randomized controlled trial . Obstetrics and Gynecology . 122 . 2 Pt 1 . 201–9 . August 2013 . 23857539 . 10.1097/AOG.0b013e31829a2dd6 . 31090241 . free .
  25. Varlas VN, Bostan G, Nasui BA, Bacalbasa N, Pop AL . Is Misoprostol Vaginal Insert Safe for the Induction of Labor in High-Risk Pregnancy Obese Women? . Healthcare . 9 . 4 . 464 . April 2021 . 33919898 . 8070889 . 10.3390/healthcare9040464 . free .
  26. Web site: Safety Information, Cytotec (misoprostol) Tablets. U.S. Food and Drug Administration (FDA). 16 March 2017. 11 December 2012. https://web.archive.org/web/20170120123024/http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm330991.htm. 20 January 2017. dead.
  27. Web site: Misoprostol (marketed as Cytotec) Information. U.S. Food and Drug Administration (FDA). 17 August 2020. 10 July 2015. https://web.archive.org/web/20200527035726/https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/misoprostol-marketed-cytotec-information. 27 May 2020. live.
  28. Wali S, Balfoussia D, Touqmatchi D, Quinn S . Misoprostol for open myomectomy: a systematic review and meta-analysis of randomised control trials . BJOG . 128 . 3 . 476–483 . February 2021 . 32613769 . 10.1111/1471-0528.16389 . 220307235 .
  29. Web site: Medical methods for first trimester abortion. World Health Organization (WHO) . 4 February 2016. dead. https://web.archive.org/web/20160214074838/http://apps.who.int/rhl/fertility/abortion/dgguide/en/. 14 February 2016.
  30. Harvey SM, Beckman LJ, Castle MA, Coeytaux F . 30491792 . Knowledge and perceptions of medical abortion among potential users . Family Planning Perspectives . 27 . 5 . 203–7 . 1 October 1995 . 9104607 . 10.2307/2136276 . 2136276 .
  31. News: The Dawn of the Post-Clinic Abortion. The New York Times. 28 August 2014. 4 February 2016. 0362-4331. Bazelon E . live. https://web.archive.org/web/20160428103240/http://www.nytimes.com/2014/08/31/magazine/the-dawn-of-the-post-clinic-abortion.html. 28 April 2016.
  32. Web site: Medical methods for first trimester abortion. The WHO Medical Reproductive Library. 22 June 2014. dead. https://web.archive.org/web/20140802174632/http://apps.who.int/rhl/fertility/abortion/dgguide/en/. 2 August 2014.
  33. Book: Safe abortion : technical and policy guidance for health systems . World Health Organization . 9789241548434. Second. Geneva. 812323067. 2012.
  34. Web site: Mifepristone. The American Society of Health System Pharmacists. 25 February 2023. 18 January 2023. live. 22 December 2015. https://web.archive.org/web/20151222083002/http://www.drugs.com/monograph/mifepristone.html.
  35. http://drjengunter.wordpress.com/2013/07/27/what-is-the-mexican-abortion-pill-and-how-safe-is-it/ What is the "Mexican abortion pill" and how safe is it?
  36. Web site: Annotated Bibliography on Misoprostol Alone for Early Abortion. Gynuity Health Projects. 22 August 2006. live . https://web.archive.org/web/20070929071156/http://www.rhtp.org/news/publications/documents/Miso%20for%20Pregnancy%20Termination.Bibliography.pdf. 29 September 2007.
  37. Web site: Annotated Bibliography - Misoprostol for Early Abortion . Gynuity Health Projects . 1 September 2004 . 25 June 2023 . 18 May 2022 . https://web.archive.org/web/20220518184738/https://gynuity.org/resources/annotated-bibliography-misoprostol-for-early-abortion . live .
  38. Book: Providing medical abortion in low-resource settings. 2009. Gynuity Health Projects. 4. 2. live . https://web.archive.org/web/20160222095552/http://gynuity.org/downloads/clinguide_maguide2nd_edition_en.pdf. 22 February 2016. 31 August 2015.
  39. Web site: Instructions for Use: Abortion Induction with Misoprostol in Pregnancies up to 9 Weeks LMP. Gynuity Health Projects . 2003. 24 August 2006. live . https://web.archive.org/web/20070929071204/http://www.rhtp.org/news/publications/documents/Miso%20for%20Pregnancy%20Termination.IFU.English.pdf#search=%22%20site%3Awww.rhtp.org%20misoprostol%20abortion%20success%20rate%22. 29 September 2007.
  40. Rasheedy R, Tamara TF, Allam IS, Abbas AM, Essam El-Din Abd El Salam N, Ferhad Ahmed A . Vaginal misoprostol before copper IUD insertion after previous insertion failure: a double-blind, placebo-controlled, parallel-group, randomised clinical trial . The European Journal of Contraception & Reproductive Health Care . 24 . 3 . 222–226 . June 2019 . 31112079 . 10.1080/13625187.2019.1610871 . 160014019 .
  41. ACOG Practice Bulletin No. 200: Early Pregnancy Loss . Obstetrics and Gynecology . 132 . 5 . e197–e207 . November 2018 . 30157093 . 10.1097/AOG.0000000000002899 . American College of Obstetricians Gynecologists' Committee on Practice Bulletins—Gynecology . 13149908 .
  42. Practice bulletin no. 143: medical management of first-trimester abortion . Obstetrics and Gynecology . 123 . 3 . 676–92 . March 2014 . 24553166 . 10.1097/01.AOG.0000444454.67279.7d . American College of Obstetricians Gynecologists . 23951273 .
  43. Lemmers M, Verschoor MA, Kim BV, Hickey M, Vazquez JC, Mol BW, Neilson JP . 6 . Medical treatment for early fetal death (less than 24 weeks) . The Cochrane Database of Systematic Reviews . 2019 . CD002253 . June 2019 . 6 . 31206170 . 6574399 . 10.1002/14651858.CD002253.pub4 .
  44. Villar J, Gülmezoglu AM, Hofmeyr GJ, Forna F . 24561459 . Systematic review of randomized controlled trials of misoprostol to prevent postpartum hemorrhage . Obstetrics and Gynecology . 100 . 6 . 1301–12 . December 2002 . 12468178 . 10.1016/S0029-7844(02)02371-2 .
  45. O'Brien P, El-Refaey H, Gordon A, Geary M, Rodeck CH . Rectally administered misoprostol for the treatment of postpartum hemorrhage unresponsive to oxytocin and ergometrine: a descriptive study . Obstetrics and Gynecology . 92 . 2 . 212–4 . August 1998 . 9699753 . 10.1016/S0029-7844(98)00161-6 .
  46. Lokugamage AU, Sullivan KR, Niculescu I, Tigere P, Onyangunga F, El Refaey H, Moodley J, Rodeck CH . 6 . A randomized study comparing rectally administered misoprostol versus Syntometrine combined with an oxytocin infusion for the cessation of primary post partum hemorrhage . Acta Obstetricia et Gynecologica Scandinavica . 80 . 9 . 835–9 . September 2001 . 11531635 . 10.1034/j.1600-0412.2001.080009835.x . 23335277 . free .
  47. Bradley SE, Prata N, Young-Lin N, Bishai DM . Cost-effectiveness of misoprostol to control postpartum hemorrhage in low-resource settings . International Journal of Gynaecology and Obstetrics . 97 . 1 . 52–6 . April 2007 . 17316646 . 10.1016/j.ijgo.2006.12.005 . 23593148 .
  48. Derman RJ, Kodkany BS, Goudar SS, Geller SE, Naik VA, Bellad MB, Patted SS, Patel A, Edlavitch SA, Hartwell T, Chakraborty H, Moss N . 22275092 . 6 . Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial . Lancet . 368 . 9543 . 1248–53 . October 2006 . 17027730 . 10.1016/S0140-6736(06)69522-6 .
  49. Book: Sanghvi H, Zulkarnain M, Chanpong G . Blouse A, Lewison D . 2009 . Prevention of Postpartum Hemorrhage at Home Birth: A Program Implementation Guide . . live . https://web.archive.org/web/20131206122217/http://pdf.usaid.gov/pdf_docs/PNADX368.pdf . 6 December 2013 .
  50. Prata N, Passano P, Bell S, Rowen T, Potts M . New hope: community-based misoprostol use to prevent postpartum haemorrhage . Health Policy and Planning . 28 . 4 . 339–46 . July 2013 . 22879523 . 10.1093/heapol/czs068 . free .
  51. Tassi A, Parisi N, Londero AP . Misoprostol administration prior to intrauterine contraceptive device insertion: a systematic review and meta-analysis of randomised controlled trials . Eur J Contracept Reprod Health Care . 25 . 1 . 76–86 . February 2020 . 31914331 . 10.1080/13625187.2019.1706079 . 210120219 . 21 June 2022 . 29 June 2022 . https://web.archive.org/web/20220629032412/https://figshare.com/articles/dataset/Misoprostol_administration_prior_to_intrauterine_contraceptive_device_insertion_a_systematic_review_and_meta-analysis_of_randomised_controlled_trials/11555661 . live .
  52. ((DMKG study group)). Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis . Journal of Neurology . 250 . 5 . 542–545 . May 2003 . 12736732 . 10.1007/s00415-003-1032-1 . 36493785 .
  53. Di Stefano G, Truini A, Cruccu G . Current and Innovative Pharmacological Options to Treat Typical and Atypical Trigeminal Neuralgia . Drugs . 78 . 14 . 1433–1442 . September 2018 . 30178160 . 6182468 . 10.1007/s40265-018-0964-9 .
  54. Web site: Cytotec- misoprostol tablet . DailyMed . 9 July 2021 . 25 June 2023 . 18 April 2023 . https://web.archive.org/web/20230418121539/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ab12da7-5731-4e06-bf1c-bc3f2e711f12 . live .
  55. Wu HL, Marwah S, Wang P, Wang QM, Chen XW . Misoprostol for medical treatment of missed abortion: a systematic review and network meta-analysis . Scientific Reports . 7 . 1 . 1664 . May 2017 . 28490770 . 5431938 . 10.1038/s41598-017-01892-0 . 2017NatSR...7.1664W . Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License .
  56. Web site: Cytotec 200mcg Tablets - Summary of Product Characteristics (SmPC) . (emc) . 26 April 2021 . 25 June 2023 . 1 July 2022 . https://web.archive.org/web/20220701225414/https://www.medicines.org.uk/emc/product/1642/smpc . live .
  57. Briggs GG, Wan SR . Drug therapy during labor and delivery, part 2 . American Journal of Health-System Pharmacy . 63 . 12 . 1131–9 . June 2006 . 16754739 . 10.2146/ajhp050265.p2 .
  58. Book: Wagner M . Born in the USA: how a broken maternity system must be fixed to put mothers and infants first . University of California Press . Berkeley . 2006 . 0-520-24596-2., which cites:

    Wing DA, Paul RH . A comparison of differing dosing regimens of vaginally administered misoprostol for preinduction cervical ripening and labor induction . American Journal of Obstetrics and Gynecology . 175 . 1 . 158–64 . July 1996 . 8694043 . 10.1016/s0002-9378(96)70267-3 .

    Wing DA, Rahall A, Jones MM, Goodwin TM, Paul RH . Misoprostol: an effective agent for cervical ripening and labor induction . American Journal of Obstetrics and Gynecology . 172 . 6 . 1811–6 . June 1995 . 7778637 . 10.1016/0002-9378(95)91416-1 .

  59. , which cites:

    Weeks A, Alfirevic Z . 13063131 . Oral misoprostol administration for labor induction . Clinical Obstetrics and Gynecology . 49 . 3 . 658–71 . September 2006 . 16885670 . 10.1097/00003081-200609000-00023 .

  60. Moreno JJ . 1513449 . Eicosanoid receptors: Targets for the treatment of disrupted intestinal epithelial homeostasis . European Journal of Pharmacology . 796 . 7–19 . February 2017 . 27940058 . 10.1016/j.ejphar.2016.12.004 .
  61. Book: Lipids in Health and Nutrition . 9781845698386 . Tyman JH . January 1999 . Elsevier . 10 May 2022 . 29 June 2022 . https://web.archive.org/web/20220629032411/https://books.google.com/books?id=1A6kAgAAQBAJ&dq=%22inventor+of+misoprostol%22&pg=PA125 . live .
  62. Book: False Choices: The Faux Feminism of Hillary Rodham Clinton . 9781784784638 . Featherstone L . June 2016 . Verso Books . 10 May 2022 . 29 June 2022 . https://web.archive.org/web/20220629032412/https://books.google.com/books?id=Fm7nDwAAQBAJ&dq=%22misoprostol%22+%22searle%22+%22Rumsfeld%22&pg=PT129 . live .
  63. Goldberg AB, Wing DA . Induction of labor: the misoprostol controversy . Journal of Midwifery & Women's Health . 48 . 4 . 244–8 . 2003 . 12867908 . 10.1016/S1526-9523(03)00087-4 .
  64. , which cites:

    American College of Obstetricians and Gynecologists . American College of Obstetricians and Gynecologists . Induction of labor with misoprostol . ACOG Committee Opinion No. 228 . Washington, DC . November 1999.

    American College of Obstetricians and Gynecologists . American College of Obstetricians and Gynecologists . Response to Searle's drug warning on misoprostol . ACOG Committee Opinion No. 248 . Washington, DC . November 1999.

  65. Web site: List of nationally authorized medicinal products . 29 June 2022 . 2 November 2021 . https://web.archive.org/web/20211102122935/https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-labour-induction-list-nationally-authorised-medicinal-products/00010353/202005_en.pdf . live .
  66. Web site: List of nationally authorised medicinal products . 26 June 2023 . 3 March 2022 . https://web.archive.org/web/20220303093147/https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-labour-induction-list-nationally-authorised-medicinal-products/00010353/201905_en.pdf . live .
  67. Costa SH, Vessey MP . 30907894 . Misoprostol and illegal abortion in Rio de Janeiro, Brazil . Lancet . 341 . 8855 . 1258–61 . May 1993 . 8098402 . 10.1016/0140-6736(93)91156-G .
  68. Coêlho HL, Teixeira AC, Cruz M, Gonzaga SL, Arrais PS, Luchini L, La Vecchia C, Tognoni G . 6 . Misoprostol: the experience of women in Fortaleza, Brazil . Contraception . 49 . 2 . 101–10 . February 1994 . 8143449 . 10.1016/0010-7824(94)90084-1 .
  69. Barbosa RM, Arilha M . The Brazilian experience with Cytotec . Studies in Family Planning . 24 . 4 . 236–40 . 1993 . 8212093 . 10.2307/2939191 . 2939191 .
  70. Rocha J . Brazil investigates drug's possible link with birth defects . BMJ . 309 . 6957 . 757–8 . September 1994 . 7950553 . 2540993 . 10.1136/bmj.309.6957.757a .
  71. Gonzalez CH, Vargas FR, Perez AB, Kim CA, Brunoni D, Marques-Dias MJ, Leone CR, Correa Neto J, Llerena Júnior JC, de Almeida JC . 6 . Limb deficiency with or without Möbius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy . American Journal of Medical Genetics . 47 . 1 . 59–64 . August 1993 . 8368254 . 10.1002/ajmg.1320470113 .
  72. News: John Leland (journalist) . Leland J . Abortion Might Outgrow Its Need for Roe v. Wade . . 2 October 2005 . 6 March 2014 . live . https://web.archive.org/web/20130518132249/http://www.nytimes.com/2005/10/02/weekinreview/02leland.html . 18 May 2013 .
  73. News: In Mexican Pill, a Texas Option for an Abortion. 14 July 2013. The New York Times. 13 July 2013. Eckholm E . live. https://web.archive.org/web/20130714154112/http://www.nytimes.com/2013/07/14/us/in-mexican-pill-a-texas-option-for-an-abortion.html. 14 July 2013.
  74. News: The Rise of the DIY Abortion in Texas . Hellenstein E . The Atlantic . 27 June 2014 . live . https://web.archive.org/web/20170302015432/https://www.theatlantic.com/health/archive/2014/06/the-rise-of-the-diy-abortion-in-texas/373240/ . 2 March 2017 .
  75. News: Sanger-Katz M, Miller CC . 30 October 2022 . Legal Abortions Fell Around 6 Percent in Two Months After End of Roe . en-US . The New York Times . 8 February 2023 . 0362-4331 . 8 February 2023 . https://web.archive.org/web/20230208135146/https://www.nytimes.com/2022/10/30/upshot/legal-abortions-fall-roe.html . live .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Misoprostol".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.